EMA’s human medicines committee (CHMP) has recommended granting conditional marketing authorisation for the oral antiviral medicine Paxlovid for the treatment of COVID-19. The applicant is Pfizer Europe MA EEIG.

The Committee recommended authorising Paxlovid for treating COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of the disease becoming severe.

In December 2021, the medicine was approved in the United States and the United Kingdom. They were also purchased by Italy, Germany and Belgium.